Company intelligence / Profile preview

CNSide Diagnostics

Houston, Texas, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

CNSide CSF assay achieved high clinical utility in the FORESEE trial—sensitivity 2.8x higher than cytology, influenced treatment in >90% LM cases, and is anticipated to launch commercially in 2025 for earlier, accurate LM diagnosis and monitoring[1][4][5].

Therapeutic areas: Oncology
Modalities: DeviceMolecular diagnosticImmunocytochemistryFluorescence in situ hybridizationNext generation sequencingCell enumeration assay
Industry: Molecular Diagnostics

Partnerships

Collaboration/license with Plus Therapeutics (parent)clinical trial sites (NCI Designated Cancer Centers incl. MD Anderson, UT Southwestern, Mays Cancer Center, Baylor Scott & White, Texas Oncology)

Beyond the preview

Go deeper on CNSide Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNSide Diagnostics.

Explore the full profile